Group 1 - The core viewpoint of the news is that Samsung Medical has shown strong financial performance in 2024, with significant growth in revenue and net profit [2][3] Group 2 - As of April 25, 2025, Samsung Medical's stock closed at 26.22 yuan, down 0.64%, with a turnover rate of 1.17% and a trading volume of 164,000 shares, amounting to a transaction value of 436 million yuan [1] - On April 25, 2025, the capital flow for Samsung Medical indicated a net inflow of 7.95 million yuan from institutional investors and 17.06 million yuan from retail investors, while retail investors had a net outflow of 25.02 million yuan [1][3] - As of March 31, 2025, the number of shareholders for Samsung Medical decreased to 16,400, a reduction of 898 shareholders or 5.2%, while the average shareholding increased to 86,200 shares [1][3] Group 3 - Samsung Medical's 2024 annual report highlights a total revenue of 14.6 billion yuan, representing a year-on-year increase of 27.38%, and a net profit attributable to shareholders of 2.26 billion yuan, up 18.69% year-on-year [2][3] - The company's net profit after deducting non-recurring items reached 2.20 billion yuan, reflecting a year-on-year growth of 31.92% [2] - In Q4 2024, Samsung Medical reported a quarterly revenue of 4.167 billion yuan, a year-on-year increase of 33.35%, and a quarterly net profit of 444 million yuan, up 7.11% year-on-year [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance meets market expectations, with 2024 revenue projected at 14.6 billion yuan, a year-on-year increase of 27.4%, and net profit attributable to shareholders at 2.26 billion yuan, up 18.7% year-on-year [8] - The overseas localization strategy is progressing steadily, with overseas revenue reaching 2.714 billion yuan in 2024, a 38% increase year-on-year, and a backlog of overseas orders at 5.748 billion yuan, up 27% year-on-year [8] - Domestic revenue from power distribution and utilization is expected to grow steadily, with a projected increase of 10-15% [8] - The rehabilitation hospital business is gaining scale, with revenue of 3.258 billion yuan in 2024, a 17% increase year-on-year [8] - Cost control measures have been effective, with operating expenses increasing by 23% year-on-year, while the expense ratio decreased by 0.6 percentage points [8] Financial Summary - Total revenue for 2023 is 11.463 billion yuan, with projections of 14.6 billion yuan for 2024, 18.315 billion yuan for 2025, and 25.017 billion yuan for 2027 [1][9] - Net profit attributable to shareholders is expected to grow from 1.904 billion yuan in 2023 to 4.316 billion yuan in 2027, reflecting a compound annual growth rate of approximately 30% [1][9] - The company's earnings per share (EPS) is projected to increase from 1.35 yuan in 2023 to 3.06 yuan in 2027 [1][9] - The price-to-earnings (P/E) ratio is expected to decrease from 19.43 in 2023 to 8.57 in 2027, indicating improving valuation [1][9]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 38.02 RMB [6][9]. Core Insights - The company achieved a revenue of 14.6 billion RMB in 2024, representing a year-on-year increase of 27.38%, slightly above the previous expectation of 14.424 billion RMB. The net profit attributable to the parent company was 2.26 billion RMB, up 18.69% year-on-year, although slightly below the prior expectation of 2.337 billion RMB [1][4]. - The company is successfully expanding its dual main businesses and markets, with continuous improvement in gross margins. The outlook for the company's dual main business is optimistic, with expectations for sustained rapid growth [1][4]. Revenue and Profitability - In 2024, the company’s revenue from the power distribution and medical services segments was 11.12 billion RMB and 3.26 billion RMB, respectively, with year-on-year increases of 31.8% and 17.1%. The overall gross margin was 34.72%, an increase of 0.73 percentage points year-on-year [2][4]. - The company reported a cash dividend payout ratio of 55.12% in 2024, with a dividend yield of 2.89% [2]. Order Backlog and Market Expansion - As of the end of 2024, the company had an order backlog of 13.202 billion RMB, a year-on-year increase of 25.81%. Domestic orders accounted for 7.454 billion RMB, up 24.88%, while overseas orders reached 5.748 billion RMB, up 27.03% [3]. - The company has made significant strides in expanding its domestic customer base and has seen notable achievements in overseas markets, particularly in Europe and Latin America [3]. Profit Forecast and Valuation - The forecast for net profit attributable to the parent company for 2025-2027 is 2.92 billion RMB, 3.57 billion RMB, and 4.31 billion RMB, with year-on-year growth rates of 29.21%, 22.31%, and 20.75%, respectively [4][5]. - The report assigns a price-to-earnings (PE) ratio of 17 for the smart power distribution segment and 27 for the medical services segment for 2025, reflecting the company's leading position in various sub-sectors of smart power distribution [4][5].

登录新浪财经APP 搜索【信披】查看更多考评等级 公司代码：601567 公司简称：三星医疗 宁波三星医疗电气股份有限公司2024年年度报告摘要 第一节 重要提示 1、本年度报告摘要来自年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到http://www.sse.com.cn网站仔细阅读年度报告全文。 2、本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、完整 性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 3、公司全体董事出席董事会会议。 4、立信会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 5、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟以本次实施权益分派股权登记日登记的总股本（扣除回购专用账户的股份）为基数，向股东每10 股派发现金红利（含税）8.90元。截至本公告披露日，公司总股本为1,411,006,571股，扣除回购专用账 户股份11,510,742股，公司可参与利润分配的总股数为1,399,495,829股，以此计算预计合计派发现金红 利约人民币1,245,551,2 ...

■证券代码：601567 证券简称：三星医疗 公告编号：临2025-028 宁波三星医疗电气股份有限公司 关于续聘立信会计师事务所为公司2025年度 财务及内控审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●拟续聘的会计师事务所名称：立信会计师事务所（特殊普通合伙） 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗潘序伦博士于1927年在上海创 建，1986年复办，2010年成为全国首家完成改制的特殊普通合伙制会计师事务所，注册地址为上海市， 首席合伙人为朱建弟先生。立信是国际会计网络BDO的成员所，长期从事证券服务业务，新证券法实 施前具有证券、期货业务许可证，具有H股审计资格，并已向美国公众公司会计监督委员会 （PCAOB）注册登记。 截至2024年末，立信拥有合伙人296名、注册会计师2,498名、从业人员总数10,021名，签署过证券服务 业务审计报告的注册会计师743名。 立信2024年业务收入（未经审计）50.01亿元，其中审计业务收入35.16亿元，证券业务收入 ...

业绩简评 4 月 24 日，公司发布 24 年报&25 一季报，24 年实现营业收入 146.0 亿元，同比+27.4%,归母净利润 22.6 亿元，同比+18.7%，扣非归 母净利润 22.0 亿元，同比+31.9%；25Q1 实现营业收入 36.3 亿元， 同比+20.0%；归母净利润 4.9 亿元，同比+34.3%，扣非归母净利 润 4.6 亿元，同比+22.6%，Q1 业绩略超预期。在手订单方面，24 年 132.0 亿元，同比+25.8%；25 年一季度 157.2 亿元，同比+26.1%。 公司发布 2025-2027 年股东分红回报规划，计划每年现金分红比 例拟不低于 45%，在有条件的情况下可以进行中期利润分配。 经营分析 海外配用电深化本地化经营、推进配电、新能源桩逆储业务出海。 海外已形成 5 生产基地+11 销售中心的业务布局，辐射 70 多个国 家/地区，海外生产基地产能在海外业务中的占比达 50%，24 年海 外实现营收 27.1 亿元，同比+38.4%，海外在手订单 57.5 亿元， 同比+27.0%。1）用电：高端市场持续深耕，24 年德国市场累计取 得电表订单约 5000 万元 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5][11]. Core Viewpoints - The company reported a revenue of 14.6 billion RMB for 2024, a year-on-year increase of 27.4%, and a net profit attributable to shareholders of 2.26 billion RMB, up 18.7% year-on-year [2]. - The company has a robust order backlog, with 13.2 billion RMB for 2024, reflecting a 25.8% year-on-year growth, and 15.72 billion RMB for Q1 2025, up 26.1% year-on-year [2]. - The company plans to distribute at least 45% of its profits as cash dividends annually from 2025 to 2027, with potential mid-term profit distributions [2]. Performance Analysis - The overseas business has established a significant presence with 5 production bases and 11 sales centers, generating 2.71 billion RMB in revenue for 2024, a 38.4% increase year-on-year [2]. - In the domestic market, the company has maintained a leading position in the power distribution sector, with significant contracts awarded, including 1.29 billion RMB from Southern Power Grid, a 68.3% increase year-on-year [3]. - The medical services segment achieved a revenue of 3.26 billion RMB in 2024, growing 17.1% year-on-year, with a gross margin of 34.3% [4]. Financial Forecasts - The company is projected to achieve revenues of 18.0 billion RMB, 22.04 billion RMB, and 26.48 billion RMB for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 23%, 22%, and 20% [5]. - The net profit attributable to shareholders is expected to reach 2.87 billion RMB, 3.50 billion RMB, and 4.22 billion RMB for the same years, with growth rates of 27%, 22%, and 21% respectively [5]. - The current price-to-earnings (P/E) ratio is projected to be 13, 11, and 9 for the years 2025, 2026, and 2027 [5].

本报记者 邬霁霞 4月24日晚间，宁波三星医疗电气股份有限公司（以下简称"三星医疗"）发布了2024年年度报告。报告期内，公司实现营 业收入146亿元，同比增长27.38%；归属于上市公司股东的净利润22.59亿元，同比增长18.69%。 三星医疗相关负责人表示，报告期内，公司以智能配用电与医疗服务双主业为战略支点，通过持续强化核心竞争力，不仅 实现经营业绩稳健增长，更在市场开拓与业务创新上多点突破。 智能配用电业务迎来丰收 智能配用电业务板块是三星医疗业绩增长的核心引擎。2024年，该业务实现营收111.20亿元，同比增长31.81%。截至2024 年12月31日，公司在手订单总额达132.02亿元，同比增长25.81%。 海外市场的突破性进展尤为瞩目。2024年，三星医疗海外营业收入达27.14亿元，同比增长38.40%。截至年末，公司海外 在手订单规模攀升至57.48亿元，同比增长27.03%。其中，海外配电订单达11.98亿元，同比增长166.30%，成为公司海外业务新 的增长极。 具体来看，三星医疗持续推进本地化经营策略，报告期内，公司海外生产基地产能在海外业务中的占比已达50%。在海外 用电市场， ...

证券代码：601567 证券简称：三星医疗 公告编号：临 2025-028 宁波三星医疗电气股份有限公司 关于续聘立信会计师事务所为公司2025年度 财务及内控审计机构的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 拟续聘的会计师事务所名称：立信会计师事务所（特殊普通合伙） 2024年度立信为693家上市公司提供年报审计服务，审计收费8.54亿元，同行业上 市公司审计客户14家。 2、投资者保护能力 截至 2024 年末，立信已提取职业风险基金 1.66 亿元，购买的职业保险累计赔偿 限额为 10.50 亿元，相关职业保险能够覆盖因审计失败导致的民事赔偿责任。 4、诚信记录 立信近三年因执业行为受到刑事处罚无、行政处罚5次、监督管理措施43次、自 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗潘序 伦博士于1927年在上海创建，1986年复办，2010年成为全国首家完成改制的特殊普通 合伙制会计师事务所，注册地址为上海市 ...

联系地址：浙江省宁波市鄞州工业园区（宁波市鄞州区姜山镇） 联系邮箱：stock@mail.sanxing.com 2024 环境、社会和 (ESG) Report 联系我们 公司治理（ESG）报告 Environmental, Social, and Governance 目录CONTENTS 报告编制说明 01 | 02 | 议题重要性评估 | 06 | | --- | --- | --- | | | 双重重要性分析 | 06 | | | 利益相关方沟通、尽职调查 | 06 | | | 议题重要性分析结论 | 08 | | 03 | ESG 治理 | 10 | | ESG 治理架构 | 10 | | --- | --- | | ESG 管理机制 | 11 | | 04 | 绿色低碳，自然共生 | 12 | | --- | --- | --- | | | 环境管理 | 12 | | | 应对气候变化 | 16 | | | 能源管理 | 19 | | | 资源利用与循环经济 | 21 | | | 污染物与废弃物管理 | 23 | 01 关于三星医疗 03 05 创新突破，优质服务 26 研发与创新 26 保障电 ...